SciGen Ltd (SIE) Moves Up 12% on Dec 5

December 5, 2017 - By Marie Mckinney

Shares of SciGen Ltd (ASX:SIE) last traded at 0.028, representing a move of 12%, or 0.003 per share, on volume of 2,049 shares. After opening the trading day at 0.028, shares of SciGen Ltd traded in a close range. SciGen Ltd currently has a total float of 552.27 million shares and on average sees 8,089 shares exchange hands each day. The stock now has a 52-week low of 0.015 and high of 0.07.

This Is Why S&P/ASX 200 Is Up 4.7% For The Year

S&P/ASX 200 is a leading market index that features Australia’s top 200 companies ranked based on market capitalization. SciGen Ltd is one of many involved in trades. The index first went online in April of 2,000 after inheriting all the data from All Ordinaries. The index does not have restrictions on the kind of companies that can be listed as long as one meets the minimum eligibility requirements.

ASX 200 Highs and Lows

Since its inception, the index all time high stands at 6828.70 points recorded in November 2007. The index boasts of an all-time low of 1358.50 points registered in November 1992 and inherited from All Ordinaries.

The index currently covers 80% of Australia’s equity market something that has made it a reliable tool for gauging the health of the country’s equity market. ASX 200 is also liquidperfect from addressing all kinds of investment needs for managers who need to diversity in their portfolio. Good liquidity of SciGen Ltd attracted traders at the market.

S&P/ ASX 200 is market-capitalization weighted, meaning its rating can only move up or down, based price changes of stocks listed. Weighted points are not in any way affected by changes in market capitalization not tied to stock prices. Unlike other indexes, ASX 200 does to take into consideration-restricted stocks normally issued to strategic investor’s, governments or venture capitalists as these are deemed strategic holdings mostly considered log term investments.

Listing Requirements

Companies that would wish to be listed in the index must first have their shares listed on the country’s national bourse, the ASX. Liquidity of a stock is another factor that is usually taken into consideration prior to a company being listed. The index also ensures that no single company dominates trading.

Rebalancing of the index usually takes place every three months in a bid to ensure that all the stocks listed meet the minimum requirement. In the just concluded rebalancing carried out on September 16, 2016, six companies were dropped and consequently replaced by six others that had met the minimum requirement.

The index rebalancing is normally carried out by a five-panel ‘index committee’ with the next one slated for December 16, 2016. While rebalancing can reduce the number of stocks listed, the committee cannot list more than 200 companies. Fortunately, SciGen Ltd is one of them.

Some of the sectors that feature prominently in the index include utilities, financials, and Healthcare. Financials account for a huge chunk of the index’s total weighted points, at 40% with the second one accounting for less than 20%. The index total equity capitalization on the other hand accounts for 80% of Australian Securities Exchange total capitalization.

ASX 200 Performance

The S&P ASX 200 is currently up by 4.7% for the year as institutional and retail investors continue to scramble for positions in some of the companies with solid growth prospects. Strong corporate governance is one of the reasons that most investors are showing strong interest in the country’s top tier companies most of which are listed in the ASX 200.

Australia also boasts of one of the lowest interest rate environment in the developed world seen as a key drawer of investments from investors abroad. Companies like SciGen Ltd are the safe haven for many.

More recent SciGen Ltd (ASX:SIE) news were published by: which released: “Publishers withdraw more than 120 gibberish papers” on February 24, 2014. Also published the news titled: “How computer-generated fake papers are flooding academia” on February 26, 2014.‘s news article titled: “Biosimilar market is projected to be worth USD 32 billion worldwide by 2025 …” with publication date: November 12, 2015 was also an interesting one.

SciGen Ltd, a biotechnology company, develops, makes, and markets recombinant human health care biotechnology derived products in the areas of endocrinology, gastroenterology, immunology, paediatrics, neurology, and oncology care worldwide. The company has market cap of $15.46 million. It offers SciLin, a recombinant human insulin expressed in E.coli for treating diabetes; SciTropin A, a human growth hormone synthesized in E.coli cells; and SciLocyte, a recombinant granulocyte colony stimulating factor used to prevent and treat the decrease of white blood cells resulting from chemotherapy. It currently has negative earnings. The firm also provides Heri Injection used to treat malignant tumors, hepatitis, and other immunodeficiency diseases; SciCosal Activator for symptomatic relief, as well as helps to clean the wound and accelerate healing process; Zonegran, an adjunctive anti-epileptic drug to treat adult patients with partial seizures with or without secondary generalization; Zinc – S injection for parenteral nutrition; and ZINC –I syrup for treating and preventing zinc deficiency, psoriasis, and diarrhea.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By1 Marie Mckinney

Automatic Stock Updates

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: